Literature DB >> 20587844

Bilateral percutaneous nephrostomy as treatment for severe hemorrhagic cystitis.

Daniel A Pérez Fentes1, Ana Puñal Pereira, Pablo Lorenzo González, Camilo García Freire, Serafín Novás Castro, Miguel Blanco Parra.   

Abstract

OBJECTIVE: To report a case of severe hemorrhagic cystitis successfully treated by bilateral percutaneous nephrostomy.
METHODS: The case of a 67-year-old female patient who had monosymptomatic gross hematuria with clots is reported.
RESULTS: Standard conservative treatments failed and the patient developed a clot-retention plugged bladder. Endoscopic evacuation and electrocoagulation of bleeding areas was unsuccessful. Due to persistent hematuria and development of renal failure and hemodynamic instability, bilateral percutaneous nephrostomy was performed. At 24 hours, hematuria ceased, patient recovered hemodynamic stability, and no additional blood transfusions were required.
CONCLUSIONS: Bilateral percutaneous nephrostomy may be a valuable option for the treatment of hemorrhagic cystitis when standard conservative measures have failed and as a prior step to performance of other more invasive procedures.

Entities:  

Mesh:

Year:  2010        PMID: 20587844

Source DB:  PubMed          Journal:  Arch Esp Urol        ISSN: 0004-0614            Impact factor:   0.436


  2 in total

1.  Conservative treatment of concomitant extraperitoneal bladder rupture and intrabladder blood clot formation: Case report of application of ureteral catheterization.

Authors:  Chih-Yuan Fu; Chun-Han Shih; Po-Yen Chang; Chi-Hao Hsiao; Yu-Chun Wang; Ray-Jade Chen
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

2.  Percutaneous nephrostomy performed on kidneys with a thin renal cortex: a retrospective study of daily urine output in 46 nephrostomy procedures.

Authors:  Chia Hsing Lu; Yi-Sheng Liu; Hong-Ming Tsai; Ming-Tsung Chuang; Chiung-Yu Chen; Yi-Shan Tsai
Journal:  Radiol Med       Date:  2013-07-20       Impact factor: 3.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.